Acute Bronchiolitis Clinical Trial
Official title:
High Flow Nasal Cannula Weaning in Acute Bronchiolitis - an Open-label Randomized Controlled Trials
The goal of this clinical study is to compared two different strategies to end high flow nasal cannula treatment in acute bronchiolitis. This study compared the immediate ending of high flow treatment to weaning strategy, in which the flow rate is gradually decreased. The aim is to assess if the immediate ending shortens the hospitalization time and whether it is a safe strategy.
Acute bronchiolitis is the most common cause of hospitalization among infants in Finland, with its primary etiology being the RS- virus. Acute bronchiolitis is defined in Finland as an infant's first respiratory distress before the age of 1. There is no effective pharmacological treatment for acute bronchiolitis. High-flow nasal cannula therapy has been shown in large randomized trials to reduce the risk of intensive care unit admission for children. High-flow nasal cannulas are typically used at a flow rate of 2 liters per kilogram per minute. Despite widespread use, there is insufficient evidence to determine whether high-flow therapy should be discontinued abruptly or gradually tapered. Observational studies indicate that the majority of units opt for abrupt discontinuation. Common criteria for discontinuation include weaning off supplemental oxygen and maintaining normal oxygenation on room air for 4-6 hours. Gradual weaning has been shown in observational studies to prolong hospitalization compared to immediate cessation of therapy. In a randomized controlled trial conducted in a pediatric intensive care unit, direct discontinuation shortened the duration of treatment by up to two days. However, there have been no previous randomized trials conducted on bronchiolitis patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01469845 -
The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis
|
Phase 3 | |
| Completed |
NCT02962505 -
Continuous Regional Analysis Device for Neonate Lung
|
||
| Recruiting |
NCT02984046 -
Acute Bronchiolitis and Severity Markers: Interest in Protein CC16
|
N/A | |
| Completed |
NCT01875757 -
Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life
|
Phase 3 | |
| Completed |
NCT01871857 -
7% Hypertonic Saline for Acute Bronchiolitis
|
Phase 4 | |
| Completed |
NCT06139029 -
Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis
|
Early Phase 1 | |
| Not yet recruiting |
NCT03915197 -
Acute Bronchiolitis in Infants and Allergic Asthma
|
N/A | |
| Completed |
NCT03171142 -
Effect of Heliox on RSV Bronchiolitis
|
Phase 3 | |
| Completed |
NCT04245202 -
Comparison of High Flow Nasal Cannula and Standard Face Mask Oxygen Therapy in Children With Bronchiolitis
|
N/A | |
| Not yet recruiting |
NCT06441162 -
Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis
|
Phase 4 | |
| Recruiting |
NCT02093715 -
FeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma
|
N/A | |
| Not yet recruiting |
NCT03880903 -
Hypertonic Saline Inhalation in Acute Bronchiolitis
|
Phase 4 | |
| Completed |
NCT04748159 -
Effects of Prone Positioning on Vital Parameters in Infants With Acute Bronchiolitis
|
N/A | |
| Active, not recruiting |
NCT04613180 -
Evaluation of the Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis
|
Phase 4 | |
| Completed |
NCT02029040 -
Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis
|
N/A | |
| Recruiting |
NCT03753802 -
Evaluation of the Effects of Respiratory Physiotherapy in Infants With Moderate Acute Bronchiolitis
|
N/A | |
| Withdrawn |
NCT01660867 -
Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department
|
Phase 4 |